Search Results for "cancer"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for cancer. Results 241 to 250 of 599 total matches.
Sonidegib (Odomzo) for Basal Cell Carcinoma
The Medical Letter on Drugs and Therapeutics • Feb 29, 2016 (Issue 1489)
have been implicated in the development
of several cancers.2 The transmembrane protein
smoothened homolog (SMO ...
The FDA has approved the hedgehog pathway
inhibitor sonidegib (Odomzo – Novartis) for oral
treatment of locally advanced basal cell carcinoma
that cannot be treated with surgery or radiation or
has recurred following such treatment. Vismodegib
(Erivedge), another oral hedgehog pathway inhibitor,
was approved earlier for the same indication and also
for treatment of metastatic basal cell carcinoma.
Fentanyl Buccal Tablet (Fentora) for Breakthrough Pain
The Medical Letter on Drugs and Therapeutics • Sep 24, 2007 (Issue 1270)
with cancer. An oral transmucosal fentanyl
lozenge on a stick (Actiq, and others) is also available ...
The FDA has approved a transmucosal tablet formulation of fentanyl citrate (Fentora - Cephalon) for management of breakthrough pain in opioid-tolerant patients with cancer. An oral transmucosal fentanyl lozenge on a stick (Actiq, and others) is also available for this indication, and is widely used off-label for chronic, non-cancer pain as well.
Glucarpidase (Voraxaze) for Methotrexate Toxicity
The Medical Letter on Drugs and Therapeutics • Mar 05, 2012 (Issue 1385)
, and in high doses
can cause nephrotoxicity. Patients receiving cancer
chemotherapy with high-dose ...
The FDA has approved glucarpidase (Voraxaze – BTG
International) for treatment of toxic plasma methotrexate
concentrations (>1 micromole per liter) in patients
with delayed methotrexate clearance due to impaired
renal function. Glucarpidase has been available in the
US since 2007 under a compassionate use open-label
treatment protocol (Clinical Trials and Consulting
Services, 1-877-398-9829), which will remain in effect
until the drug becomes commercially available later
this year. There is currently a shortage of IV methotrexate
in the US.
Ashwagandha Supplements
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
, and various cancers.1
AVAILABILITY — Ashwagandha is available commercially
in tablets, capsules, liquid ...
Ashwagandha is an herb extracted from the roots of
an evergreen shrub (Withania somnifera) found in
India that has been used as a "tonic" for centuries.
No specific constituent has been identified as an
active ingredient. Herbal supplements containing
ashwagandha, which is also known as winter cherry
and Indian ginseng, are widely promoted now in the
US for treatment of pain, anxiety, stress, fatigue, sleep
disturbances, cognitive decline, diabetes, arthritis,
male infertility, and various cancers.
Acupuncture
The Medical Letter on Drugs and Therapeutics • May 08, 2006 (Issue 1234)
at best as an adjunct to anesthesia, particularly for postoperative pain and nausea.
8,9
Cancer ...
Acupuncture is the practice of inserting fine needles for therapeutic purposes into points on the skin known as acupoints. In traditional Chinese medicine theory, these points arefound along channels that conduct "qi" (pronounced "chee"), or energy. In addition to insertion of needles, acupoints can be stimulated by heat, electrical current or just pressure.
Colonoscopy Preparations
The Medical Letter on Drugs and Therapeutics • Jan 21, 2013 (Issue 1408)
Exams
Colonoscopy remains the preferred method of colorectal
cancer screening.1 Many patients consider ...
Colonoscopy remains the preferred method of colorectal
cancer screening. Many patients consider
cleansing the bowel in preparation for colonoscopy
the most unpleasant part of the procedure, but inadequate
bowel preparation significantly lowers the diagnostic
yield.
Preservation of Ovarian Function During Chemotherapy
The Medical Letter on Drugs and Therapeutics • Jun 28, 2010 (Issue 1341)
trial in 80 young women
(average age 30 + 3.5 years) with breast cancer
found a decrease in premature ...
Chemotherapy can result in premature menopause and infertility in young women. Pretreatment fertility
counseling followed by appropriate action may prevent some of these undesirable consequences.
In Brief: Respiratory Depression with Gabapentinoids
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
-neuropathic pain,
anxiety, and insomnia, and hot flashes in women with breast
cancer.2-5 Often prescribed ...
The FDA has required new warnings in the labels of
gabapentin (Neurontin, and others) and pregabalin (Lyrica,
Lyrica CR, and generics) about the risk of life-threatening or
fatal respiratory depression in patients with respiratory risk
factors. Respiratory risk factors include chronic obstructive
pulmonary disease (COPD) and concurrent use of opioids
or other CNS depressants. Elderly patients are also at
increased risk.
Trimetrexate
The Medical Letter on Drugs and Therapeutics • Jan 27, 1989 (Issue 784)
has a terminal serum half-life reported to be from 10 to 34 hours (JT
Lin et al, Cancer Res, 47:609, 1987 ...
Trimetrexate glucuronate (Parke-Davis), an investigational drug, is now available in the USA from the National Institute of Allergy and Infectious Diseases (NIAID) for treatment of selected AIDS patients with Pneumocystis carinii pneumonia (PCP). For this indication, trimetrexate is always used concurrently with leucovorin (Wellcovorin; and others).
Fludarabine
The Medical Letter on Drugs and Therapeutics • Sep 20, 1991 (Issue 853)
, as it has
been for two years, through the National Cancer Institute.
CHRONIC LYMPHOCYTIC LEUKEMIA — CLL is the most ...
Fludarabine phosphate (Fludara - Berlex), an analog of vidarabine (Vira-A), was recently approved by the U.S. Food and Drug Administration for treatment of patients with refractory chronic lymphocytic leukemia (CLL). The drug has not yet been marketed but is still available, as it has been for two years, through the National Cancer Institute.